Bristol-Myers Squibb (China) Investment Co. Ltd.

Primary objective: To evaluate the efficacy of golcadomide + R-CHOP vs. placebo-R-CHOP on investigator-assessed PFS in subjects with untreated high-risk large B-cell lymphoma. Secondary objectives: In subjects with untreated high-risk large B-cell lymphoma: To evaluate the efficacy of golcadomide + R-CHOP vs. placebo-R-CHOP on OS, investigator-assessed EFS, IRAC-assessed CMR, and MRD negativity at EOT. To evaluate the efficacy of golcadomide + R-CHOP vs. placebo-R-CHOP on IRAC-assessed PFS, investigator-assessed OR, investigator-assessed CMR, PFS24, DoR, PFS2, and relative dose intensity exposure of CHOP cytotoxic components; to compare disease symptoms, function, and overall HRQoL between golcadomide + R-CHOP and placebo-R-CHOP as measured by EORTCQLQ-C30 and FACT-LymS. Compare the safety of golcadomide + R-CHOP with placebo-R-CHOP. Compare the effects of golcadomide + R-CHOP with placebo-R-CHOP on HCRU, overall health status, and utility.

Primary objective: Evaluate the PK characteristics of BMS-986435 after a single dose in healthy Chinese subjects Secondary objectives: Evaluate the safety and tolerability of BMS-986435 after a single dose in healthy Chinese subjects; Evaluate the PD of BMS-986435 after a single dose in healthy Chinese subjects by dose level

To evaluate the efficacy and safety of oral ozanimod in Chinese subjects with relapsing multiple sclerosis